SOTIO unveils promising preclinical data on SOT109, a next-gen ADC targeting Cadherin-17 (CDH17) for colorectal cancer

CAR-T Digest - August 2020

03 March 2025: SOTIO unveils promising preclinical data on SOT109, a next-gen ADC targeting Cadherin-17 (CDH17) for colorectal cancer

SOTIO Biotech presented the first preclinical data on SOT109, an antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17), at the 15th World ADC London 2025. The data suggest SOT109 could be a best-in-class treatment for colorectal and gastrointestinal (GI) cancers
SOT109 utilizes Synaffix’s ADC platform with an exatecan-based payload, demonstrating potent tumor-killing ability with strong selectivity and minimal off-target toxicity due to CDH17’s restricted expression in normal tissues
Preclinical studies in mouse models showed SOT109’s strong anti-tumor activity, including complete responses, and high tolerability at doses up to 150 mg/kg, with further toxicity studies in non-human primates confirming a favorable therapeutic index
SOT109 is expected to enter first-in-human phase 1 clinical trials in 2026, with an Investigational New Drug (IND) application planned for Q2 2026, marking a major advancement in ADC development for GI cancers